Subclinical Cardiovascular Disease in Psoriatic Disease
| Status: | Recruiting |
|---|---|
| Conditions: | Peripheral Vascular Disease, Cardiology, Cardiology, Cardiology, Cardiology |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | 18 - 90 |
| Updated: | 1/9/2019 |
| Start Date: | August 1, 2017 |
| End Date: | December 1, 2019 |
| Contact: | Michael Garshick |
| Email: | micahel.garshick@nyumc.org |
| Phone: | 212 263 4004 |
This study will look at how chronic inflammation seen in psoriatic disease translates into
the increased atherosclerotic and thrombotic risk and how treatment reduces this CVD risk.
The Aim of this study is to 1) Evaluate the association between moderate to severe psoriatic
disease and measures of vascular function. 2) Evaluate the association between moderate to
severe psoriatic disease and measures of thrombotic risk. 3) Understand how traditional
medications used in cardiovascular disease (CVD) prevention such as aspirin and statins
affect vascular function and thrombotic risk in those with moderate to severe psoriatic
disease.
the increased atherosclerotic and thrombotic risk and how treatment reduces this CVD risk.
The Aim of this study is to 1) Evaluate the association between moderate to severe psoriatic
disease and measures of vascular function. 2) Evaluate the association between moderate to
severe psoriatic disease and measures of thrombotic risk. 3) Understand how traditional
medications used in cardiovascular disease (CVD) prevention such as aspirin and statins
affect vascular function and thrombotic risk in those with moderate to severe psoriatic
disease.
Cardiovascular disease (CVD) remains the leading cause of death in the US. Five modifiable
risk factors: smoking, hyperlipidemia, diabetes, hypertension and obesity, account for 50% of
CVD mortality between the ages of 45 - 79.1 These traditional cardiac risk factors dictate
who to treat with primary prevention measures but do not take into account patient-specific
disease states such as psoriatic disease including psoriasis and psoriatic arthritis, which
predispose to chronic inflammation. Patients with psoriatic disease have an increased risk of
atherosclerotic heart disease and myocardial infarctions compared to matched controls.
risk factors: smoking, hyperlipidemia, diabetes, hypertension and obesity, account for 50% of
CVD mortality between the ages of 45 - 79.1 These traditional cardiac risk factors dictate
who to treat with primary prevention measures but do not take into account patient-specific
disease states such as psoriatic disease including psoriasis and psoriatic arthritis, which
predispose to chronic inflammation. Patients with psoriatic disease have an increased risk of
atherosclerotic heart disease and myocardial infarctions compared to matched controls.
Inclusion Criteria:
- Subjects with a history of moderate to severe psoriatic disease
- Group 2: Healthy subjects without known psoriatic disease or cardiovascular disease
Exclusion Criteria:
- Unable to speak Spanish or English
- Active smoking (within the past year)
- Autoimmune, rheumatologic or inflammatory disease which are not psoriasis or psoriatic
arthritis
- Known active cancer receiving treatment
- Pregnancy
- Anemia (hemoglobin < 9 mg/dl) or thrombocytopenia (Platelet count <75), or
thrombocytosis (Platelet count >600)
- A history of severe bleeding or bleeding disorders
- Current medication use which interact with either aspirin or atorvastatin
- Chronic kidney disease (CrCl < 30ml/min)
- Congestive heart failure
- Currently taking aspirin or a statin.
- NSAID use within the past 48 hours
We found this trial at
1
site
550 1st Ave
New York, New York 10016
New York, New York 10016
(212) 263-7300
Principal Investigator: Jeffrey Berger, MD
Phone: 212-263-4004
New York University School of Medicine NYU School of Medicine has a proud history that...
Click here to add this to my saved trials
